Motility & Functional GI · Article 122

Do GLP-1 Drugs Increase the Risk of Retained Gastric Contents or Aspiration During Endoscopy?

GLP-1 aspiration risk requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

GLP-1 aspiration risk clinical reference — Related free clinical resource: Clinical Pharmacology.

GLP-1 aspiration risk: practical clinical approach

This page focuses on GLP-1 aspiration risk with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for GLP-1 aspiration risk

Clinical takeaway: For GLP-1 aspiration risk, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: GLP-1 drugs are associated with delayed gastric emptying and observational studies have reported more retained gastric contents at endoscopy in some users. However, aspiration is uncommon and the magnitude of any independent aspiration-risk increase remains uncertain. Risk appears to depend on symptoms, dose escalation, indication, comorbidity, fasting, and anesthesia technique. Clinicians should distinguish the relatively common finding of retained food from the much rarer outcome of clinically important aspiration.

Retained contents are not the same as aspiration

Multiple retrospective studies suggest increased retained gastric material in some GLP-1 users, but retained food is an intermediate outcome. Actual aspiration events remain rare, making precise risk estimation difficult.

Who appears most vulnerable

Active nausea or vomiting, early treatment/dose escalation, higher doses, known motility disorders and inadequate fasting increase concern. Stable asymptomatic long-term users may have substantially lower risk.

Clinical implications

If significant retained food is found unexpectedly, the endoscopist must consider procedure indication, airway protection, whether visualization is adequate, and whether the procedure should be aborted or rescheduled.

Practical clinical algorithm

Ask about GLP-1 exposure and symptoms at preassessment.
Apply standard fasting plus risk-based modifications.
For high-risk patients, consider 24-hour liquid diet or postponement.
If retained food is encountered, stop and reassess aspiration and visualization risk.
Use airway-protective anesthesia when urgent endoscopy cannot safely be delayed.

Common mistakes to avoid

Equating any retained food with gastroparesis.
Assuming aspiration risk is zero because events are uncommon.
Assuming the drug alone explains retained food.
Continuing a nonurgent procedure despite poor visualization and substantial gastric contents.
Using observational associations as proof of a fixed causal risk.

Trainee takeaway

GLP-1 therapy clearly can influence gastric emptying; the clinically important question is which patient has enough retained-content risk to change the endoscopy or anesthesia plan.

Frequently asked questions

Does a GLP-1 drug cause gastroparesis in every user?

No. Effects on gastric emptying and symptoms vary greatly.

Can retained food occur despite fasting?

Yes, particularly when gastric emptying is delayed.

Is aspiration common?

No. It is uncommon, but potentially serious, which is why risk-based precautions matter.

References

1. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Endoscopy and Diagnostic Imaging. Part I. CAPstone Academic Publishers; 2012.

3. Al Hashash JG, Thompson CC, Wang AY. AGA Rapid Clinical Practice Update on GLP-1 receptor agonists prior to endoscopy. Clin Gastroenterol Hepatol. 2024.

4. Kindel TL, et al. Multi-society clinical practice guidance for GLP-1 receptor agonists in the perioperative period. Surg Endosc. 2024.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions